X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA MERCK LTD AJANTA PHARMA/
MERCK LTD
 
P/E (TTM) x 20.0 26.6 75.0% View Chart
P/BV x 8.6 3.0 289.6% View Chart
Dividend Yield % 0.7 0.9 73.3%  

Financials

 AJANTA PHARMA   MERCK LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
MERCK LTD
Dec-16
AJANTA PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs1,7201,060 162.3%   
Low Rs1,103623 177.0%   
Sales per share (Unadj.) Rs194.6632.4 30.8%  
Earnings per share (Unadj.) Rs45.245.7 98.9%  
Cash flow per share (Unadj.) Rs50.362.3 80.7%  
Dividends per share (Unadj.) Rs8.0011.00 72.7%  
Dividend yield (eoy) %0.61.3 43.4%  
Book value per share (Unadj.) Rs132.0388.8 34.0%  
Shares outstanding (eoy) m88.7716.60 534.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.3 545.1%   
Avg P/E ratio x31.218.4 169.6%  
P/CF ratio (eoy) x28.113.5 207.8%  
Price / Book Value ratio x10.72.2 494.0%  
Dividend payout %17.724.1 73.5%   
Avg Mkt Cap Rs m125,29913,969 897.0%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m2,5701,487 172.9%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m17,27510,498 164.6%  
Other income Rs m166242 68.6%   
Total revenues Rs m17,44210,741 162.4%   
Gross profit Rs m5,8071,135 511.5%  
Depreciation Rs m451276 163.6%   
Interest Rs m490-   
Profit before tax Rs m5,4741,102 496.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460343 425.3%   
Profit after tax Rs m4,014759 528.9%  
Gross profit margin %33.610.8 310.8%  
Effective tax rate %26.731.1 85.6%   
Net profit margin %23.27.2 321.4%  
BALANCE SHEET DATA
Current assets Rs m7,6396,410 119.2%   
Current liabilities Rs m2,7158,828 30.7%   
Net working cap to sales %28.5-23.0 -123.7%  
Current ratio x2.80.7 387.6%  
Inventory Days Days4358 74.9%  
Debtors Days Days7938 204.9%  
Net fixed assets Rs m6,9141,406 491.6%   
Share capital Rs m177166 106.6%   
"Free" reserves Rs m11,4426,286 182.0%   
Net worth Rs m11,7216,455 181.6%   
Long term debt Rs m1490-   
Total assets Rs m14,8148,828 167.8%  
Interest coverage x112.9NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.21.2 98.1%   
Return on assets %27.48.6 319.0%  
Return on equity %34.211.8 291.3%  
Return on capital %46.517.1 272.5%  
Exports to sales %55.18.3 665.9%   
Imports to sales %6.021.0 28.5%   
Exports (fob) Rs m9,527869 1,095.8%   
Imports (cif) Rs m1,0382,209 47.0%   
Fx inflow Rs m10,422959 1,087.0%   
Fx outflow Rs m1,6782,612 64.2%   
Net fx Rs m8,744-1,653 -528.9%   
CASH FLOW
From Operations Rs m3,2641,070 304.9%  
From Investments Rs m-2,093-750 279.2%  
From Financial Activity Rs m-1,186-150 791.5%  
Net Cashflow Rs m-15171 -8.7%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 1.6 18.2 8.5%  
FIIs % 7.6 1.0 760.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 29.1 58.4%  
Shareholders   20,968 28,591 73.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare AJANTA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 22, 2017 09:28 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - NOVARTIS COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS